Eisai Co., Ltd. and Biogen Inc. announced on January 6th that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb, which has the brand name in the United States of LEQEMBITM, for the treatment of Alzheimer’s disease. The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of Alzheimer’s disease. Newt’s guest is Dr. Marwan Sabbagh, MD. He is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program and a professor in the Department of Neurology at Barrow Neurological Institute and was one of the leading doctors of the study.
See omnystudio.com/listener for privacy information.
Episode 524: Washington’s Farewell Address
Episode 523: Balanced Budget Amendment
Episode 522: Newt Answers Your Questions with Chairman Jim Jordan
Episode 521: Rethinking Public Employee Unions
Episode 520: The Ten Habits of Good Citizens
Episode 519: The American Imperative
Episode 518: The 118th Congress
Episode 517: The Bidens
Episode 516: Drug Prices in America – Worth the Cost?
Episode 515: Liz Lev on the Sistine Chapel
Episode 514: Stephen Hunter on “The Bullet Garden”
Episode 513: Never Forget Our People Were Always Free
Episode 512: The Debt Ceiling Debate
Episode 511: The Immortals – General George Marshall
Episode 510: The Real Race Revolutionaries
Episode 508: Newt Answers Your Questions
Episode 507: Speaker Kevin McCarthy
Episode 506: GOPAC Tapes – It's Morning in America, Again ...
Episode 505: GOPAC Tapes – An Effective Team for Real Change
Create your
podcast in
minutes
It is Free